City Therapeutics prices upsized IPO at $18.00 per share
FROM THE WIRE · MANILATIMES.NET
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) ('City” or 'City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the pricing of its upsized…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA roughly $200 million biotech IPO signals investor appetite for the sector, but remains ordinary deal flow.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01City Therapeutics priced its upsized IPO at $18.00 per share.
- 02The offering comprises 11,111,111 shares, with expected gross proceeds of about $200.0 million.
- 03The underwriters have a 30-day option to buy up to an additional 1,666,666 shares.
- 04The company is a clinical-stage biotech developing next-generation RNA interference therapeutics.